Nanomix Corp. (NNMX)

[Trend-Setter]

WOW!!!MERGER!!!...MERGER!!! in the works! THIS IS GOING TO BE A COVID 19 TESTING PLAY! Boston Therapeutics (BTHE) is merging with NanoMix, Inc. NanoMix will be the surviving entity.

SEC 8-k Filed
Agreement and Plan of Merger
On January 26, 2021, Boston Therapeutics, Inc., a Delaware corporation (the “Company”), BTHE Acquisition Inc., a California corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Nanomix, Inc., a California corporation (“Nanomix”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Nanomix, with Nanomix continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. Nanomix has developed an advanced mobile Point-of-Care (POC) diagnostic system that can be used in performing a wide range of in vitro diagnostic tests in many environments. Our goal is to provide laboratory quality testing for time sensitive medical conditions, at the first point of contact that a patient has with the healthcare system, no matter where that occurs. The Nanomix eLab® system is CE Marked, a 510(k) is currently in process, and Emergency Use Applications (EUA) for COVID testing has been submitted to the FDA. We intend to market and sell this system for the detection and diagnosis of a variety of time sensitive medical conditions.....

https://www.sec.gov/Archives/edgar/data/1473579/000121390021006198/ea134438-8k_bostontherap.htm

This gonna be huge!
Nanomix is the leader in the development of mobile, affordable point-of-care diagnostics. We offer a handheld testing platform and assays that provide rapid, accurate, quantitative information for use in settings where time-to-diagnosis is critical for clinical decision-making and improved patient care.

Our goal is to expand access to quality healthcare by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote, or alternative settings.

We have tests available or under development to aid in the diagnosis of sepsis, acute kidney injury, and SARS-CoV-2. Results are returned in just 10 minutes.

https://nano.com/

This explains the uncommon trading activity of this dormant stock lately. LOL... NOT SELLING A SINGLE SHARE HERE.